Recombinant Vaccines Market: By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus, Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others) By Distribution Channel (Hospitals & Retail Pharmacies, Government Suppliers, and Others) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Recombinant Vaccines Market was estimated to be valued at USD 11,507.3 million in 2022, and it is expanded to grow at a significant CAGR of 5.3% over 2023-2029. The main factors driving the global recombinant vaccine market are the full-fledged recombinant properties in providing the effectiveness and safety of the patient getting immunized. Additionally, the increasing prevalence of viral diseases in countries worldwide is anticipated to boost the market. The growing population and strict regulations for infant immunization are projected to drive the overall market. Another significant driving force is the improvement of technology in the fields of recombinant DNA technology, genetics, and proteomics, which is boosting vaccination R&D. As a result, the number of clinical trials is increasing. Based on the Route of Administration, the parenteral segment has a significant share of the global recombinant vaccines market with a share of 87.3% in 2022 the global market and is projected to grow at 4.9% CAGR from 2023 - 2029. The parenteral vaccines, such as enhanced potency inactivated polio vaccine, Haemophilus influenzae type B, hepatitis B virus (HBV), and other non-mucosal vaccines, have been highly effective in preventing systemic disease during subsequent exposure to natural infection.

Recent Market Developments:

  • In Jan 2021, Merck, a leading science and technology company, announced the acquisition of Amptek, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck's capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.
  • In April 2021, Sanofi and GSK announce that they have signed a letter of intent to enter collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.

Recombinant Vaccines Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

Asia Pacific
Recombinant Vaccines Market Dynamics

The market for recombinant vaccines is predicted to develop as the incidence of zoonotic diseases rises, and new technologies emerge. Furthermore, the marketplace is likely to be fueled by continued investment in vaccine research and development and growing public awareness of vaccines. The high cost associated with recombinant vaccines would inhibit the market.

Recombinant Vaccines Market Segmentation

By Type
  • Subunit
  • Live Attenuated
By Route Administration
  • Parenteral
  • Oral
By Disease Indication
  • Human Papillomavirus
  • Hepatitis B
  • Rotavirus
  • Herpes Zoster
  • Meningococcal B
  • Others
By Geography
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • North America

Frequently Asked Questions

The CAGR of the recombinant vaccines market is 5.3% over the forecast period (2023 - 2029)    

Merck KGaA, Novartis AG, GlaxoSmithKline Plc., GC Biopharma, Bayer AG, Sanofi SA, Pfizer Inc.  

The Asia Pacific is the fastest-growing region for the recombinant vaccines market

Key Features of the Reports

  • The recombinant vaccines market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Merck KGaA
  • Novartis AG
  • GlaxoSmithKline Plc.
  • GC Biopharma
  • Bayer AG
  • Sanofi SA
  • Pfizer Inc.
  • Bharat Biotech.

Adjacent Markets